ScreenerHero

SLDB Solid Biosciences Inc.

NAS · US · Healthcare · Biotechnology · solidbio.com
6.850USD-1.01%Mkt Cap: 734.49M $P/E: —

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrop…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap734.49M USD
Enterprise Value384.48M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-174.32M USD
Revenue/Share—
Last Price6.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.06
PEG—
EV/EBITDA-1.83
EV/Revenue—
P/S—
P/B1.94
EPS (TTM)-1.89
EPS (Forward)-1.70
52W Range
3.79040% of range11.44
52W High11.44 USD
52W Low3.790 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-96.84%
ROA-74.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-156.29M USD
CapEx (TTM)1.15M USD
FCF Margin—
FCF Yield-16.10%
Net Debt-357.52M USD
Net Debt/EBITDA1.70
Balance Sheet
Debt/Equity0.12
Current Ratio13.82
Quick Ratio13.21
Book Value/Sh3.56 USD
Cash/Share3.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 28, 2022
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.62 USD
Upside (mean)+171.8%
Target Range11.00 USD – 26.00 USD
11.00+171.8% to mean26.00
# Analysts13
Ownership
Shares Out.107.23M
Float64.81M
Insiders0.68%
Institutions107.41%
Short Interest
Short Ratio19.5d
Short % Float18.13%
Short % Out.15.95%
Shares Short17.11M
Short (prev mo.)16.62M
Technical
SMA 508.735 (-21.6%)
SMA 2007.597 (-9.8%)
Beta2.47
S&P 52W Chg16.45%
Avg Vol (30d)1.17M
Avg Vol (10d)1.38M
Technical Indicators
RSI (14)30.8
MACD-0.6049
MACD Signal-0.4776
MACD Hist.-0.1273
BB Upper10.30 USD
BB Middle8.078 USD
BB Lower5.860 USD
BB Width54.91%
ATR (14)0.4643 USD
Vol Ratio (20d)0.56x